Sunshine Biopharma Inc (SBFM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has a cash flow conversion efficiency ratio of -0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-727.80K) by net assets ($24.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sunshine Biopharma Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Sunshine Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Sunshine Biopharma Inc for a breakdown of total debt and financial obligations.
Sunshine Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunshine Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hollywood Bowl Group PLC
LSE:BOWL
|
0.215x |
|
SUNation Energy Inc.
NASDAQ:SUNE
|
0.110x |
|
Golden Tobacco Limited
NSE:GOLDENTOBC
|
0.032x |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
-0.079x |
|
Cape Range Ltd
AU:CAG
|
0.011x |
|
Megapower Makmur TBK PT
JK:MPOW
|
0.022x |
|
Vintage Energy Ltd
AU:VEN
|
0.191x |
|
abrdn Asian Income Fund Limited
LSE:AAIF
|
0.031x |
Annual Cash Flow Conversion Efficiency for Sunshine Biopharma Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Sunshine Biopharma Inc from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Sunshine Biopharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $23.50 Million | $-12.53 Million | -0.533x | -28.87% |
| 2023-12-31 | $21.21 Million | $-8.78 Million | -0.414x | -70.51% |
| 2022-12-31 | $21.63 Million | $-5.25 Million | -0.243x | +97.19% |
| 2021-12-31 | $211.66K | $-1.83 Million | -8.642x | -1355.36% |
| 2020-12-31 | $-954.84K | $-657.30K | 0.688x | +2.10% |
| 2019-12-31 | $-735.38K | $-495.80K | 0.674x | -92.67% |
| 2018-12-31 | $-55.75K | $-512.81K | 9.198x | +870.28% |
| 2017-12-31 | $-573.36K | $-543.52K | 0.948x | -36.73% |
| 2016-12-31 | $-209.70K | $-314.18K | 1.498x | +3.10% |
| 2015-12-31 | $-597.04K | $-867.64K | 1.453x | +4.58% |
| 2014-12-31 | $-387.58K | $-538.60K | 1.390x | -98.10% |
| 2013-12-31 | $-7.71K | $-564.40K | 73.203x | +1411.63% |
| 2012-12-31 | $70.43K | $-393.05K | -5.581x | -93.36% |
| 2011-12-31 | $103.00K | $-297.30K | -2.886x | -62.59% |
| 2010-12-31 | $196.22K | $-348.32K | -1.775x | -1597.95% |
| 2009-12-31 | $97.80K | $-10.22K | -0.105x | -106.72% |
| 2008-12-31 | $-17.71K | $-27.53K | 1.555x | +767.03% |
| 2007-12-31 | $13.39K | $-3.12K | -0.233x | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor … Read more